Original reporting and analysis on the stories shaping biotech.
Alumis lost more than half its stock value after its TYK2 inhibitor envudeucitinib flopped in a midstage lupus trial. The company is betting a subgroup of patients holds the key to a Phase 3 comeback, but investors aren't buying it yet.
Roche just dropped $75 million on a preclinical trispecific antibody from Chinese biopharma Simcere, with the deal potentially worth up to $1.53 billion. It's the latest (and loudest) signal that Big Pharma's China shopping spree isn't slowing down, geopolitics be damned.
Novartis just struck the largest subcutaneous delivery deal in history, paying up to $3.22 billion for technology that converts IV-drip biologics into at-home injections. The deal signals that Big Pharma's most expensive convenience upgrade is now a strategic arms race.
Novartis just dropped Phase 3 data showing its oral BTK inhibitor remibrutinib crushed an older MS drug across two major trials, with analysts projecting up to $9 billion in peak sales. The kicker: it works by turning down the immune system's thermostat instead of ripping it off the wall.
ARPA-H just dropped $125 million to fund five teams building automated, point-of-care RNA drug factories. If it works, personalized medicine could go from a nine-week wait to something closer to on-demand. The implications for rare diseases, cancer vaccines, and pandemic prep are massive.
A phage therapy biotech with $1.2 million in cash and a 97% stock collapse is rebranding as a defense and homeland security company. BiomX's transformation into Tessera Defense might be the wildest corporate pivot in recent biotech history.
Regeneron's Pasatru just became the second FDA-approved drug for FOP, a brutal rare disease that turns soft tissue into bone. The Phase 3 data showed a 90%+ reduction in new bone lesions, and Ipsen's struggling Sohonos franchise now has a serious fight on its hands.
Novo Nordisk just started selling a weight-loss pill in Germany that works about as well as the Wegovy injection. The catch? German insurance won't cover it, so patients are footing the entire bill. This is the real-world experiment that could define the future of the oral GLP-1 market.
Arsenal Biosciences just fired 99 employees, killed its clinical programs, and bet everything on a technology that barely exists in the clinic. When a company backed by $630 million torches its own playbook, it tells you something important about where cell therapy is headed.
BioNTech and Genentech killed their personalized mRNA cancer vaccine trial in colorectal cancer after a troubling survival signal. The failure raises hard questions about whether mRNA technology can leap from COVID to solid tumors, especially as rival Moderna just scored a Phase 3 win in melanoma.
A Delaware jury just hit Parse Biosciences with a $4.8 million willful infringement verdict over single-cell sequencing patents, and the real pain hasn't even started yet. Enhanced damages, attorneys' fees, and a potential injunction could reshape the competitive landscape of a $1.9 billion market.
Relaxin has been chasing a heart failure breakthrough for over a decade, failing spectacularly each time. AstraZeneca thinks it finally cracked the code by turning an IV-only hormone into a daily pill, and the first real data just dropped.
Three patient deaths forced Novartis to freeze eight autoimmune CAR-T trials, and BMS paused its own program days later. The most hyped frontier in cell therapy just hit a wall that could reshape the entire field.
The FDA commissioner reportedly tried to personally reject KalVista's rare disease drug, only to have career scientists push back and call the move legally indefensible. It's the clearest sign yet that political interference at the FDA isn't theoretical anymore.
Sanofi-backed Electra Therapeutics just filed for a Nasdaq IPO with a drug that posted 100% survival in a disease where half of patients typically die. The $100 million offering could be one of fall 2026's biggest biotech debuts.
The Trump administration's drug-pricing push just expanded beyond Big Pharma, with nine midsize biotech companies signing MFN deals that trade lower prices for tariff relief. Wall Street shrugged, but the structural squeeze on smaller companies is harder to ignore.
Samsung Biologics is going all-in on peptides with a $1.8 billion takeover bid for Swiss CDMO PolyPeptide Group. The deal is a direct play on insatiable GLP-1 manufacturing demand, and it signals that CDMO consolidation is only accelerating.
GSK's mRNA flu vaccine outperformed standard shots in Phase 2 and is heading to a pivotal Phase 3 trial. But history shows that better antibodies don't always mean better protection, and the road ahead is full of trap doors.
AstraZeneca's $6 billion lung cancer drug just got a powerful new partner. Phase III data shows Tagrisso plus Hutchmed's Orpathys extends both progression-free and overall survival in patients whose tumors outsmarted Tagrisso alone, and the strategic implications go way beyond one trial.
A small Irish medtech company just reported that its new stroke catheter reopened blocked brain arteries in 89% of patients without needing backup, and nailed it on the first try 75% of the time. In a race where every minute kills nearly 2 million neurons, those numbers could reshape how strokes are treated.
Genentech just dropped $190 million upfront (and up to $2.3 billion total) on an obesity drug that doesn't work like Ozempic. HM17321 takes a completely different approach: burning fat while actually building muscle, a trick no GLP-1 drug can pull off.
Sarepta's flagship Duchenne gene therapy just earned the FDA's most severe safety warning after fatal liver failures, and the company is cutting 36% of its workforce. What happens when gene therapy's biggest commercial success story hits a wall?
Join thousands of biotech professionals who start their day with our free, daily briefing.